VAPORHCS/OHSU J: A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to determine the side effects (both good and bad) of the combination of cabazitaxel (Jevtana) and enzalutamide (XTANDI), and to determine if the combination is effective in the treatment of Castration Resistant Prostate Cancer (CRPC).
Castration Resistant Prostate Cancer (CRPC)
-Currently progressing despite androgen suppression therapy
-No prior enzalutamide, cabazitaxel, or other chemotherapy for CRPC
-No history of seizures or current treatment with medications that lower the seizure threshold
18 - 110
Healthy Volunteers Needed
Duration of Participation
Active treatment will continue until cancer stops responding to the study therapy; at least 12 weeks and up to 2 years. Participants will be followed for long-term status for up to 5 years.
Knight Cancer Institute Clinical trials information line: Phone 503-494-1080 or email@example.com
Oregon Health & Science University